170 related articles for article (PubMed ID: 15746584)
1. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
Labropoulos SV; Fletcher JA; Oliveira AM; Papadopoulos S; Razis ED
Anticancer Drugs; 2005 Apr; 16(4):461-6. PubMed ID: 15746584
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
[TBL] [Abstract][Full Text] [Related]
4. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
[TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
6. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted treatment for dermatofibrosarcoma protuberans.
McArthur G
Semin Oncol; 2004 Apr; 31(2 Suppl 6):30-6. PubMed ID: 15176002
[TBL] [Abstract][Full Text] [Related]
8. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases.
Tatai T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Koizumi T; Sano K
Intern Med; 2016; 55(17):2507-11. PubMed ID: 27580559
[TBL] [Abstract][Full Text] [Related]
11. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
[TBL] [Abstract][Full Text] [Related]
13. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
Johnson-Jahangir H; Sherman W; Ratner D
J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
[TBL] [Abstract][Full Text] [Related]
14. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.
Shimizu A; O'Brien KP; Sjöblom T; Pietras K; Buchdunger E; Collins VP; Heldin CH; Dumanski JP; Ostman A
Cancer Res; 1999 Aug; 59(15):3719-23. PubMed ID: 10446987
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
[TBL] [Abstract][Full Text] [Related]
16. Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing.
Hong JY; Liu X; Mao M; Li M; Choi DI; Kang SW; Lee J; La Choi Y
PLoS One; 2013; 8(7):e69752. PubMed ID: 23922791
[TBL] [Abstract][Full Text] [Related]
17. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
Rutkowski P; Van Glabbeke M; Rankin CJ; Ruka W; Rubin BP; Debiec-Rychter M; Lazar A; Gelderblom H; Sciot R; Lopez-Terrada D; Hohenberger P; van Oosterom AT; Schuetze SM; ;
J Clin Oncol; 2010 Apr; 28(10):1772-9. PubMed ID: 20194851
[TBL] [Abstract][Full Text] [Related]
19. Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.
Wicherts DA; van Coevorden F; Klomp HM; van Huizum MA; Kerst JM; Haas RL; van Boven HH; van der Hage JA
World J Surg Oncol; 2013 Mar; 11():59. PubMed ID: 23496933
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]